Clinical Trials Directory

Trials / Completed

CompletedNCT03058497

Laminar Airflow in Severe Asthma for Exacerbation Reduction

A Multi-centre Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of the Effectiveness of the Nocturnal Use of a Temperature Controlled Laminar Airflow (TLA) Device (Airsonett®) in Adults With Poorly-controlled, Severe Allergic Asthma

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
240 (actual)
Sponsor
Portsmouth Hospitals NHS Trust · Other Government
Sex
All
Age
16 Years – 75 Years
Healthy volunteers
Accepted

Summary

To ascertain whether home-based nocturnal TLA usage over a 12 month period can reduce exacerbations and improve asthma control and quality of life as compared to placebo, whilst being cost-effective and acceptable to adults with poorly-controlled, severe allergic asthma.

Detailed description

We will include 222 adults, half of whom will be given a TLA device that is working, and the other half will be given a device which has been inactivated (the filtering process will be switched off, although the participants will not be able to tell that this has occurred). Which participant receives the working or deactivated device will be decided by a random process and will be unknown to the researcher and the participant. An engineering team from the manufacturer will install the device in the participants' home at the beginning of the study and be available throughout the study period to deal with any queries. All participants will continue receiving their usual treatments. Participants will be in the study for 12 months, and will report their asthma attacks to the trial team whenever they occur during this period. In addition, they will visit the trial team 4 times (after 3, 6, 9 and 12 months) to assess their asthma control and quality of life. At the end of the trial, we will invite participants at each site to join a group discussion where researchers will explore the participant's thoughts about the TLA device. At the end of their participation in the trial, all participants who have used the device for more than 6 months, regardless of their initial study group, will be offered the opportunity to keep an active device in their home free of charge for a further four years.

Conditions

Interventions

TypeNameDescription
DEVICETemperature-Controlled Laminar Airflow Device (Airsonett®)

Timeline

Start date
2014-05-01
Primary completion
2017-01-01
Completion
2017-01-01
First posted
2017-02-23
Last updated
2017-02-23

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03058497. Inclusion in this directory is not an endorsement.